Treace Medical Concepts has filed a lawsuit against Zimmer Biomet and Paragon 28 for patent infringement related to its bunion correction technologies.
Quiver AI Summary
Treace Medical Concepts, Inc. has filed a lawsuit against Zimmer Biomet Holdings and Paragon 28, alleging infringement of four patents related to its Lapiplasty® 3D Bunion Correction® technologies. The lawsuit, lodged in the U.S. District Court for Delaware, seeks injunctive relief and damages, emphasizing Treace's commitment to protecting its patents and innovations in bunion surgery. Treace, a leader in this medical field, has developed a range of surgical solutions for bunions affecting millions of Americans. The company continues to expand its patent portfolio and introduce new technologies to improve treatment outcomes for patients suffering from bunion-related deformities.
Potential Positives
- Treace Medical filed a lawsuit to protect its intellectual property, demonstrating its commitment to safeguarding its innovative technologies and investments in research.
- The lawsuit indicates Treace's position as a leader in the bunion correction market, reinforcing its reputation for pioneering 3D surgical methods.
- Treace has a substantial patent portfolio, including 80 granted U.S. patents and additional patents worldwide, which enhances its competitive edge in the industry.
- The press release highlights Treace's innovative product offerings, such as the Lapiplasty® and Adductoplasty® procedures, potentially attracting more attention from investors and stakeholders in the medical community.
Potential Negatives
- The announcement of a lawsuit against Zimmer Biomet and Paragon 28 may generate negative publicity and perception around Treace, potentially affecting investor confidence.
- The financial implications of the lawsuit, such as legal costs and potential damages, could strain Treace's resources, especially if the litigation leads to a lengthy or costly process.
- Filing a lawsuit may divert management's focus and resources away from innovation and operational activities, potentially hindering the company's growth and development efforts.
FAQ
What is the lawsuit filed by Treace Medical Concepts about?
Treace Medical Concepts has filed a lawsuit against Zimmer Biomet and Paragon 28 for patent infringement related to its Lapiplasty® technology.
What technologies are involved in Treace's lawsuit?
The lawsuit involves four patents related to Treace’s Lapiplasty® 3D Bunion Correction® technologies.
Why is Treace pursuing legal action?
Treace aims to protect its significant investments in innovative research and technology by enforcing its intellectual property rights.
How many patents does Treace Medical hold?
Treace Medical has 80 granted U.S. patents and 26 granted patents worldwide, with over 150 pending applications.
What is Treace's mission in the medical technology field?
Treace is focused on advancing the standard of care for the surgical management of bunions and related midfoot deformities.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TMCI Insider Trading Activity
$TMCI insiders have traded $TMCI stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TMCI stock by insiders over the last 6 months:
- JOHN T. TREACE (Chief Executive Officer) purchased 60,000 shares for an estimated $524,064
- SEAN F. SCANLAN (Chief Innovation Officer) sold 50,000 shares for an estimated $398,460
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TMCI Hedge Fund Activity
We have seen 68 institutional investors add shares of $TMCI stock to their portfolio, and 90 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 887,941 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,606,281
- PARKMAN HEALTHCARE PARTNERS LLC added 713,539 shares (+inf%) to their portfolio in Q1 2025, for an estimated $5,986,592
- MORGAN STANLEY removed 609,323 shares (-28.5%) from their portfolio in Q1 2025, for an estimated $5,112,219
- UBS GROUP AG removed 607,115 shares (-62.7%) from their portfolio in Q1 2025, for an estimated $5,093,694
- FIRST EAGLE INVESTMENT MANAGEMENT, LLC added 498,924 shares (+inf%) to their portfolio in Q1 2025, for an estimated $4,185,972
- DRIEHAUS CAPITAL MANAGEMENT LLC added 468,278 shares (+inf%) to their portfolio in Q1 2025, for an estimated $3,928,852
- CIBC PRIVATE WEALTH GROUP LLC added 405,257 shares (+21.5%) to their portfolio in Q1 2025, for an estimated $3,400,106
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TMCI Analyst Ratings
Wall Street analysts have issued reports on $TMCI in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/04/2025
- Lake Street issued a "Buy" rating on 01/29/2025
To track analyst ratings and price targets for $TMCI, check out Quiver Quantitative's $TMCI forecast page.
$TMCI Price Targets
Multiple analysts have issued price targets for $TMCI recently. We have seen 3 analysts offer price targets for $TMCI in the last 6 months, with a median target of $14.5.
Here are some recent targets:
- An analyst from Truist Financial set a target price of $9.5 on 03/13/2025
- Ryan Zimmerman from BTIG set a target price of $16.0 on 02/04/2025
- Ben Haynor from Lake Street set a target price of $14.5 on 12/31/2024
Full Release
PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, “Zimmer”) (NYSE: ZBH), alleging infringement of 4 patents related to Treace’s innovative Lapiplasty® 3D Bunion Correction® technologies. The suit was filed in the United States District Court for the District of Delaware, and seeks injunctive relief and damages.
“Treace Medical was the first company to develop, patent, and introduce an instrumented 3D bunion correction system for true tri-planar lapidus bunion correction and is the recognized leader in the surgical treatment of bunions. We believe that this lawsuit is necessary to protect the significant investments we have made in our pioneering research and technology, which is in the best interest of our stockholders,” said John T. Treace, Chairman, CEO and Founder of Treace. “Enforcing and defending our intellectual property helps to drive our ability to continue to innovate solutions that benefit patients.”
Treace’s patent portfolio includes 80 granted U.S. patents, with an additional 26 granted patents worldwide and over 150 pending patent applications.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn , X , Facebook and Instagram .
Contacts
:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
[email protected]
(904) 373-5940
Investors
:
Gilmartin Group
Philip Trip Taylor
[email protected]
